Sep 20, 2024
Charles Joynson, WaveData MD, has conducted some indepth analysis to try to identify early warning signs of generic shortages. Here’s the third and final instalment In the first part of this series we looked at Losartan Tabs 12.5mg 28 and at the four shortages...
Sep 19, 2024
Charles Joynson, WaveData MD, has conducted some indepth analysis to try to identify early warning signs of generic shortages. Here’s the second instalment In the first instalment of this series, we looked at Losartan Tabs 12.5mg 28 and at the four shortages of...
Sep 18, 2024
Charles Joynson, WaveData MD, has conducted some indepth analysis to try to identify early warning signs of generic shortages. Here’s the first instalment. Over the last few years, WaveData has repeatedly analysed shortages and concessions, trying to find links...
Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
Feb 8, 2024
WaveData conducted a comparison of the average market prices given to accounts (pharmacies and dispensing doctors) by respiratory product manufacturers. The average discounts given over a 10 year period are very consistent at 9%, which probably reflects the underlying...
